Long-term infusion of anti-GD2 antibody ch14.18/CHO is active and less toxic in high-risk neuroblastoma patients

Purpose: GD2 is highly expressed in neuroblastoma (NB) and specifically recognized by monoclonal antibody ch14.18/CHO (Ab). Immunotherapy with bolus infusion of ch14.18 effectively prolonged survival. We piloted a treatment with continuous infusion of ch14.18 in combination with IL2 aiming at a reduction of toxicity and maintaining immune modulation. Methods and Materials: The pain level was analyzed by validated pain scoring systems and morphine usage. Pharmacokinetics, complement-dependent- (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC), effector cell levels as well as cytokine profiles were de…